This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
'''2-(Isopropylamino)-2-(3-methoxyphenyl)cyclohexanone''' (also known as '''3-MeO-2′-Oxo-PCiPr''' and '''MXiPr''') is a novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. It is a structural analog of [[MXE]].
'''3-MeO-2′-Oxo-PCiPr''' (also known as '''MXiPr''') is a novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. It is a structural analog of [[MXE]]. The mechanism of action is not known, but it is likely an NMDA [[receptor]] [[antagonist]], producing [[dissociative]] and [[euphoric]] effects.
The circumstances surrounding MXiPr's original discovery are not known and its synthesis has not documented in the scientific literature. MXiPr first appeared on the online research chemical market in late 2020<ref>MXiPr - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=MXiPr</ref> and was marketed as a legal substitute for [[ketamine]] or [[MXE]]. The initial batch reportedly smelled like plastic and was suspected of containing impurities.
The circumstances surrounding MXiPr's origins are not known. It first appeared on the online research chemical market in late 2020<ref>MXiPr - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=MXiPr</ref> and was specifically marketed as a legal substitute for [[MXE]] or [[ketamine]]. The initial batch reportedly smelled like plastic and was suspected of containing impurities. The second batch contained a distinctly different smell of "pokemon cards".
[[Subjective effects]] are comparable to ketamine and include [[sedation]], [[motor control loss]], [[pain relief]], [[internal hallucinations]], [[conceptual thinking]], [[euphoria]], and [[disconnective effects|dissociation]]. Early anecdotal reports suggest that MXiPr exhibits two plateaus. The first plateau occurs at doses around 5-20 mg and produces a two hour long experience resembling nitrous oxide. The second plateau at doses around 20-40+ mg giving an experience similar to a ketamine k-hole, with a warmer or "dreamier" afterglow. It is not known if higher plateaus exist, and some researchers have urged caution if experimenting with higher doses. There are reports of body load occurring for up to 2 days after a small dose.
Its [[subjective effects]] are comparable to that of [[ketamine]] and [[MXE]] and include [[sedation]], [[motor control loss]], [[pain relief]], [[internal hallucinations]], [[conceptual thinking]], [[euphoria]], and [[disconnective effects|dissociation]]. Its subjective effects are described as mostly similar to [[O-PCE]] or MXE, but being more unpredictable and euphoric which makes it further away from ketamine effects-wise. It is presumed to be a strong serotonin reuptake inhibitor like MXE.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MXiPr, and it has a very brief history of human usage. Given the reports of impure batches, it is advised to purify this substance before use (please see [[MXiPr#Toxicity and harm potential|this section]] for more details). It is strongly recommended to use [[harm reduction practices]] if using this substance.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MXiPr, and it has a very brief history of human usage. Given the reports of impure batches, it is advised to purify this substance (please see [[MXiPr#Toxicity and harm potential|this section]] and send it into a chemical testing service before use.
It is strongly advised to use [[harm reduction practices]] if using this substance.
==History and culture==
==History and culture==
Line 14:
Line 16:
==Chemistry==
==Chemistry==
{{chemistry}}
MXiPr, or (IUPAC) 2-(3-Methoxyphenyl)-2-[(propan-2-yl)amino]cyclohexan-1-one, is classed as an [[arylcyclohexylamine]] drug.<ref>{{Citation | title=Explore MXiP PiHKAL · info | url=https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=14059}}</ref> It posesses an isopropyl group on the nitrogen atom of the molecule as well as a doubled-bonded oxygen atom at the 2' position of the cyclohexyl ring and a methoxy group on the 3 position of the phenyl ring, both of which it shares with [[MXE]].
MXiPr, or (IUPAC) 2-(3-Methoxyphenyl)-2-[(propan-2-yl)amino]cyclohexan-1-one, is classed as an [[arylcyclohexylamine]] drug. Specifically, an Arylcycloalkylamine<Ref>Isomer Design | https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=14059</ref>.
==Pharmacology==
==Pharmacology==
{{pharmacology}}
{{pharmacology}}
Very little is known about the pharmacology about this substance, however as an arylcyclohexamine it is reasonable to assume that it is an [[NMDA receptor antagonist]]. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].”
Very little is known about the pharmacology about this substance, however as an arylcyclohexamine it is reasonable to assume that it is an [[NMDA receptor antagonist]]. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].”
Given its structural similarity to [[MXE]] and according to anecdotal reports, this substance may be a strong serotonin reuptake inhibitor (SRI). One should avoid combining MXiPr with other drugs that act on serotonin.
==Subjective effects==
==Subjective effects==
{{EffectStub}}
{{EffectStub}}
MXiPr can be said to share similar properties to that of [[MXE]] or [[O-PCE]] but there have been some anecdotal reports that suggest that this may have a potentially higher risk of inducing [[wikipedia:Rhabdomyolysis| Rhabdomyolysis (Wikipedia)]], seizures, and amnesia. It is possible that these effects may be avoided by practicing harm reduction via keeping dosages low, usage infrequent, and avoiding combinations.
Early anecdotal reports suggest that MXiPr exhibits two plateaus: The first plateau occurs at doses around 5-20 mg and produces a two hour long experience resembling nitrous oxide, the second plateau occurs at doses around 20-40+ mg giving an experience similar to a [[Visual_disconnection#Holes.2C_spaces_and_voids|hole]], but generally considered chaotic, with a remarkably warmer or "dreamier" afterglow which can also become very euphoric. Some researchers urge caution when experimenting with higher doses. There are reports of body load occurring for up to 2 days after a small dose and seizures at very high dosages.<ref name="earlygreygreen2021">{{Citation | vauthors=((earlgreygreen)) | year=2021 | title=MXiPR consistently gives seizures at higher dosages administered IM | url=https://www.reddit.com/r/researchchemicals/comments/la97rf/mxipr_consistently_gives_seizures_at_higher/}}</ref>
MXiPr shares similar properties to that of [[MXE]] and [[O-PCE]] but there have been some anecdotal reports that suggest that this may have a potentially higher risk of inducing [[wikipedia:Rhabdomyolysis| Rhabdomyolysis (Wikipedia)]],{{citation needed}} seizures, and amnesia. It is possible that these effects may be avoided by practicing harm reduction via keeping dosages low, infrequent usage, and avoiding combinations.
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
Line 29:
Line 34:
|{{effects/physical|
|{{effects/physical|
*'''[[Effect::Sedation]]'''
*'''[[Effect::Stimulation]]''' & '''[[Effect::Sedation]]''' - At low to moderate dosages, MXiPr is primarily stimulating while at higher dosages the experience turns sedating.
*'''[[Effect::Spontaneous bodily sensations]]''' - The MXiPr "body high" can be described as a sharp, pleasurable tingling sensation which is location specific to the hands, feet, and head.
*'''[[Effect::Spontaneous bodily sensations]]''' - The MXiPr "body high" can be described as a sharp, pleasurable tingling sensation which is location specific to the hands, feet, and head.
*'''[[Effect::Perception of bodily lightness]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
*'''[[Effect::Perception of bodily lightness]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is very prevalent with MXiPr and strangely stimulating. It encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
*'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside balance and coordination is prevalent on MXiPr and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in the case of falling over and injuring oneself.
*'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside balance and coordination is prevalent on MXiPr and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in the case of falling over and injuring oneself.
*'''[[Effect::Spatial disorientation]]
*'''[[Effect::Spatial disorientation]]
Line 40:
Line 45:
*'''[[Effect::Nausea]]''' - High dose MXiPr experience can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
*'''[[Effect::Nausea]]''' - High dose MXiPr experience can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Orgasm suppression]]''' - Orgasm enhancement can also be present, even at higher doses.
*'''[[Effect::Orgasm suppression]]''' & '''[[Effect::Orgasm enhancement]]''' - Orgasm enhancement can sometimes also be present, even at higher doses, although this effect is not reliable.
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Increased blood pressure]]'''{{citation needed}} - This effect is typically present at the higher doses.{{citation needed}}
*'''[[Effect::Increased blood pressure]]'''{{citation needed}} - This effect is typically present at the higher doses.{{citation needed}}
*'''[[Effect::Increased heart rate]]'''{{citation needed}} - This effect has been reported as being more pronounced than other dissociatives, such as [[DCK]] or [[diphenidine]].
*'''[[Effect::Increased heart rate]]'''{{citation needed}} - This effect has been reported as being more pronounced than other dissociatives, such as [[DCK]] or [[diphenidine]].
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Seizure]]''' - The extent to which this effect can be produced is unknown, but it appears the likelihood of this is more pronounced than other dissociatives, and can probably be avoided by keeping dosage within reasonable levels. The likelihood is also probably increased in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
*'''[[Effect::Seizure]]'''<ref name="earlygreygreen2021"/> - The extent to which this effect can be produced is unknown, but it appears the likelihood of this is more pronounced than other dissociatives, and can probably be avoided by keeping dosage within reasonable levels. The likelihood is also probably increased in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
}}
}}
Line 62:
Line 67:
====Hallucinatory states====
====Hallucinatory states====
*'''[[Effect::Internal hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'')
*'''[[Effect::Internal hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]'', ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'')
*'''[[Effect::Machinescapes]]'''
*'''[[Effect::Machinescapes]]'''
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - This effect can be comprehensively described through its [[Internal_hallucinations#Variations|variations]] as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - This effect can be comprehensively described through its [[Internal_hallucinations#Variations|variations]] as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.
Line 71:
Line 76:
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Disinhibition]]'''
*'''[[Effect::Disinhibition]]'''
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Cognitive euphoria]]''' - The euphoria of this substance is reported to be stronger than that of other dissociatives like [[O-PCE]] but weaker than that of [[MXE]].
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Mania]]''' - Some users have reported mania on this substance. The frequency of which is undetermined. It is strongly recommended to use harm-reduction practices and not use this substance in high amounts or frequently. Most likely, it is more common than most [[arylcyclohexylamines]] but less common in occurrence compared to PCP and 3-MeO-PCP.
*'''[[Effect::Mania]]''' - Some users have reported mania on this substance. The frequency of which is undetermined. It is strongly recommended to use harm-reduction practices and not use this substance in high amounts or frequently. Most likely, it is more common than most [[arylcyclohexylamines]] but less common in occurrence compared to [[PCP]] and [[3-MeO-PCP]].
*'''[[Effect::Delusion]]''' - Most likely, it is more common than most [[arylcyclohexylamines]] but less common in occurrence compared to drugs like 3-MeO-PCP.
*'''[[Effect::Delusion]]''' - Most likely, this effect is more common with MXiPr than with most other [[arylcyclohexylamines]] but less common in occurrence compared to substances like 3-MeO-PCP.
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Memory suppression]]'''
*'''[[Effect::Memory suppression]]'''
Line 90:
Line 95:
{{effects/auditory|
{{effects/auditory|
The auditory effects of MXiPr have been described as more pronounced than other hallucinogens. These effects include:
The auditory effects of MXiPr have been described as more pronounced than other [[hallucinogens]]. These effects include:
*'''[[Effect::Auditory distortion|Distortions]]''' - These distortions are very powerful and loud enough in their volume to make the original sound completely unrecognizable. They include phasers, white noise, high pitch tones and notes, flanging, changes in pitch, echo effects, and stuttering. In particular, the frequency of the stuttering is proportionally related to the intensity of the effects, especially ego death which occurs when the stuttering becomes continuous.
*'''[[Effect::Auditory distortion|Distortions]]''' - These distortions are very powerful and loud enough in their volume to make the original sound completely unrecognizable. They include phasers, white noise, high pitch tones and notes, flanging, changes in pitch, echo effects, and stuttering. In particular, the frequency of the stuttering is proportionally related to the intensity of the effects, especially ego death which occurs when the stuttering becomes continuous.
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational MXiPr use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because MXiPr has very little history of human usage.
The toxicity and long-term health effects of recreational MXiPr use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because MXiPr has very little history of human usage.
MXiPr has anecdotally been reported to produce seizures at very high dosages.<ref name="earlygreygreen2021"/>
If one suspects that it may be impure and are still keen on taking this substance, at the very least ensure that it to goes through first-pass metabolism by taking it orally.
If one suspects that it may be impure and are still keen on taking this substance, using an oral [[route of administration]] may process the impurities though first-pass metabolism.
It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
It is strongly recommended that one use [[responsible use|harm reduction practices]] when using this substance.
Line 136:
Line 144:
Regarding its long-term health effects when used repeatedly and over excessive periods, MXiPr is suspected to exhibit similar bladder and urinary tract problems found with [[ketamine]], but to a lesser extent. This is because MXiPr is far more potent than ketamine, so significantly less of substance needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:
Regarding its long-term health effects when used repeatedly and over excessive periods, MXiPr is suspected to exhibit similar bladder and urinary tract problems found with [[ketamine]], but to a lesser extent. This is because MXiPr is far more potent than ketamine, so significantly less of substance needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Line 153:
Line 161:
==Legal status==
==Legal status==
{{LegalStub}}
{{LegalStub}}
*'''Germany:''' MXiPr is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''Hungary:''' MXiPr was made illegal to possess, produce and sell in Hungary in April 2021.<ref>[https://ec.europa.eu/growth/tools-databases/tris/index.cfm/en/search/?trisaction=search.detail&year=2021&num=225&dLang=EN Amendment of Minister for Human Capacities Decree No 55/2014 of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances, 2021/225/HU]</ref>
*[https://www.bluelight.org/xf/threads/the-big-dandy-3-meo-2%E2%80%B2-oxo-pcipr-mxipr-thread.889817/ Bluelight - The Big & Dandy 3-MeO-2′-oxo-PCiPr (MXiPr) Thread]
*[https://www.bluelight.org/xf/threads/the-big-dandy-3-meo-2%E2%80%B2-oxo-pcipr-mxipr-thread.889817/ Bluelight - The Big & Dandy 3-MeO-2′-oxo-PCiPr (MXiPr) Thread]
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
The circumstances surrounding MXiPr's origins are not known. It first appeared on the online research chemical market in late 2020[1] and was specifically marketed as a legal substitute for MXE or ketamine. The initial batch reportedly smelled like plastic and was suspected of containing impurities. The second batch contained a distinctly different smell of "pokemon cards".
Very little data exists about the pharmacological properties, metabolism, and toxicity of MXiPr, and it has a very brief history of human usage. Given the reports of impure batches, it is advised to purify this substance (please see this section and send it into a chemical testing service before use.
MXiPr first appeared for sale on the online research chemical market in late 2020.[2]
Chemistry
MXiPr, or (IUPAC) 2-(3-Methoxyphenyl)-2-[(propan-2-yl)amino]cyclohexan-1-one, is classed as an arylcyclohexylamine drug.[3] It posesses an isopropyl group on the nitrogen atom of the molecule as well as a doubled-bonded oxygen atom at the 2' position of the cyclohexyl ring and a methoxy group on the 3 position of the phenyl ring, both of which it shares with MXE.
Very little is known about the pharmacology about this substance, however as an arylcyclohexamine it is reasonable to assume that it is an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole.”
Given its structural similarity to MXE and according to anecdotal reports, this substance may be a strong serotonin reuptake inhibitor (SRI). One should avoid combining MXiPr with other drugs that act on serotonin.
Early anecdotal reports suggest that MXiPr exhibits two plateaus: The first plateau occurs at doses around 5-20 mg and produces a two hour long experience resembling nitrous oxide, the second plateau occurs at doses around 20-40+ mg giving an experience similar to a hole, but generally considered chaotic, with a remarkably warmer or "dreamier" afterglow which can also become very euphoric. Some researchers urge caution when experimenting with higher doses. There are reports of body load occurring for up to 2 days after a small dose and seizures at very high dosages.[4]
MXiPr shares similar properties to that of MXE and O-PCE but there have been some anecdotal reports that suggest that this may have a potentially higher risk of inducing Rhabdomyolysis (Wikipedia),[citation needed] seizures, and amnesia. It is possible that these effects may be avoided by practicing harm reduction via keeping dosages low, infrequent usage, and avoiding combinations.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation & Sedation - At low to moderate dosages, MXiPr is primarily stimulating while at higher dosages the experience turns sedating.
Spontaneous bodily sensations - The MXiPr "body high" can be described as a sharp, pleasurable tingling sensation which is location specific to the hands, feet, and head.
Perception of bodily lightness - This creates the sensation that the body is floating and has become entirely weightless. This effect is very prevalent with MXiPr and strangely stimulating. It encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
Motor control loss - A loss of gross and fine motor control alongside balance and coordination is prevalent on MXiPr and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in the case of falling over and injuring oneself.
Tactile suppression - This partially to entirely suppresses one's sense of touch, creating feelings of numbness within the extremities. It is responsible for the anesthetic properties of this substance.
Dizziness - Although uncommon, some people report dizziness under the influence of MXiPr, especially when used in combination with other substances.
Nausea - High dose MXiPr experience can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
Orgasm suppression & Orgasm enhancement - Orgasm enhancement can sometimes also be present, even at higher doses, although this effect is not reliable.
Seizure[4] - The extent to which this effect can be produced is unknown, but it appears the likelihood of this is more pronounced than other dissociatives, and can probably be avoided by keeping dosage within reasonable levels. The likelihood is also probably increased in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
Visual effects
Visual acuity enhancement or Visual acuity suppression - While lower doses of this compound tend to produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increased.
Cognitive euphoria - The euphoria of this substance is reported to be stronger than that of other dissociatives like O-PCE but weaker than that of MXE.
Mania - Some users have reported mania on this substance. The frequency of which is undetermined. It is strongly recommended to use harm-reduction practices and not use this substance in high amounts or frequently. Most likely, it is more common than most arylcyclohexylamines but less common in occurrence compared to PCP and 3-MeO-PCP.
Delusion - Most likely, this effect is more common with MXiPr than with most other arylcyclohexylamines but less common in occurrence compared to substances like 3-MeO-PCP.
Increased libido - This is reported to be present at lower dosage ranges.
Auditory effects
The auditory effects of MXiPr have been described as more pronounced than other hallucinogens. These effects include:
Distortions - These distortions are very powerful and loud enough in their volume to make the original sound completely unrecognizable. They include phasers, white noise, high pitch tones and notes, flanging, changes in pitch, echo effects, and stuttering. In particular, the frequency of the stuttering is proportionally related to the intensity of the effects, especially ego death which occurs when the stuttering becomes continuous.
Suppression - This effect can be described as a muffling and quieting of externally sourced sound which results in it sounding more indistinct and distant than it would usually be.
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.
The toxicity and long-term health effects of recreational MXiPr use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXiPr has very little history of human usage.
MXiPr has anecdotally been reported to produce seizures at very high dosages.[4]
If one suspects that it may be impure and are still keen on taking this substance, using an oral route of administration may process the impurities though first-pass metabolism.
As with other NMDA receptor antagonists, the chronic use of MXiPr can be considered moderately addictive with a high potential for abuse and is capable of producing psychological dependence among certain users.
When addiction has developed, cravings and withdrawal effects may occur if one suddenly stops their usage.
Tolerance to many of the effects of MXiPr develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects.
After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).
MXiPr exhibits cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of MXiPr all dissociatives will have a reduced effect.
Urinary tract effects
Regarding its long-term health effects when used repeatedly and over excessive periods, MXiPr is suspected to exhibit similar bladder and urinary tract problems found with ketamine, but to a lesser extent. This is because MXiPr is far more potent than ketamine, so significantly less of substance needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:
Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
Urinary urgency - This can be described as a sudden, compelling need to urinate.
Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Pelvic and bladder pain - Pain can develop suddenly and severely, especially since the bladder fills with urine.
Hematuria - Hematuria is visible blood in the urine.
Incontinence - This is the leakage of urine.
All of these, however, can easily be avoided by simply not using MXiPr on a daily or even weekly basis and consciously limiting one's usage of the substance.
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Germany: MXiPr is controlled under the NpSG (New Psychoactive Substances Act)[5] as of July 18, 2019.[6] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[7]
Hungary: MXiPr was made illegal to possess, produce and sell in Hungary in April 2021.[8]
↑"Anlage NpSG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
↑"§ 4 NpSG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
